====== Alexander Doroshenko ====== {{ :public_health_agencies:canada:profiledoroshenko200x300.jpeg?150|}} Dr. **Alexander Doroshenko** is an infectious disease epidemiologist and public health specialist in Alberta, Canada. His interests include evaluation of public health interventions and evidence-based public health policies. ===== Affiliations ===== ==== Alberta Health Services ==== Doroshenko is the Public Health representative for the [[AHS COVID-19 Scientific Advisory Group]] under [[Alberta Health Services]].((//2019-nCoV Scientific Advisory Group.// (2021, May 27). Alberta Health Services. https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-terms-of-reference.pdf)) ==== University of Alberta ==== Doroshenko is an Assistant Professor in the Department of Medicine, Faculty of Medicine and Dentistry at the [[:University of Alberta]].((//Alexander Doroshenko | Public Health.// University of Alberta. Retrieved January 8, 2022, from https://www.ualberta.ca/public-health/about/faculty-staff/adjunct-emeritus-faculty/doroshenko.html)) He has received funding for research through the University of Alberta from the [[:University Hospital Foundation]], which is funded by [[:pharmaceutical_companies:Takeda]], [[:pharmaceutical_companies:Biogen]], [[:pharmaceutical_companies:Boehringer Ingelheim]], [[:pharmaceutical_companies:Novartis]], [[:pharmaceutical_companies:Merck]], [[:Volvo]], [[:Edmonton Journal]], [[:Canadian National Railway]] (part owned by [[:Bill Gates]]), RBC ([[:Royal Bank of Canada]]), [[:TELUS]], [[:KPMG]], [[:Medtronic]], Scotia Capital ([[:Scotiabank]]), [[:Postmedia]], [[:Deloitte]], [[:Fidelity]], [[:London Drugs]], [[:WestJet]], [[:Aecon]], [[:PwC|PricewaterhouseCoopers]], [[:pharmaceutical_companies:Janssen]], [[:CTV News]], [[:Bell Media]], [[:Global News]], [[:Corus Entertainment]], [[:pharmaceutical_companies:Astellas]], [[:pharmaceutical_companies:Novo Nordisk]], [[:pharmaceutical_companies:Servier]], and [[:pharmaceutical_companies:Roche]].((Abbott, J. (2021). //Thank you to our donors.// In University Hospital Foundation (pp. 2–23). https://givetouhf.ca/app/uploads/2021/12/UHF-2021-HonouringDonors-WEB-v2.pdf)) ((//Annual Report 2019-2020.// University Hospital Foundation. Retrieved January 8, 2022, from https://givetouhf.ca/app/uploads/2021/08/UHF_Annual-Report-2019-2020-Revised_19412_F-pages-smaller.pdf)) ((//Annual Report 2018-2019.// University Hospital Foundation. Retrieved January 8, 2022, from https://givetouhf.ca/app/uploads/2020/10/UHF-Annual-Report-2018-19-lowres.pdf)) ===== Publications ===== * //Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review//((Somerville, M., Curran, J. A., Dol, J., Boulos, L., Saxinger, L., Doroshenko, A., Hastings, S., Reynolds, B., Gallant, A. J., Shin, H. D., Wong, H., Crowther, D., Macdonald, M., Martin-Misener, R., Comeau, J., McCulloch, H., & Tricco, A. C. (2021). //Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review.// BMJ Open, 11(12), e055781. https://doi.org/10.1136/bmjopen-2021-055781)) * Funded by the [[:SPOR Evidence Alliance]], [[:Canadian Institutes of Health Research]] (CIHR), and [[:COVID-END]]. * //Trivalent MDCK cell culture-derived influenza vaccine Optaflu® (Novartis Vaccines)//((Doroshenko, A., & Halperin, S. A. (2009). //Trivalent MDCK cell culture-derived influenza vaccine Optaflu®(Novartis Vaccines).// Expert Review of Vaccines, 8(6), 679–688. https://doi.org/10.1586/erv.09.31)) * Co-authored with [[:Scott Halperin]], who has an extensive catalogue of vaccine-related publications and was funded by [[:pharmaceutical_companies:Novartis]] for this study * In collaboration with the [[:Canadian Center for Vaccinology]] * //What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model//((Rafferty, E. R. S., McDonald, W., Osgood, N. D., Doroshenko, A., & Farag, M. (2021). //What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model.// Value in Health, 24(1), 50–60. https://doi.org/10.1016/j.jval.2020.10.004)) * Funded by [[Alberta Health Services]] and the [[:University of Alberta]] * //Decline of Influenza and Respiratory Viruses With COVID-19 Public Health Measures: Alberta, Canada//((Doroshenko, A., Lee, N., MacDonald, C., Zelyas, N., Asadi, L., & Kanji, J. N. (2021). //Decline of Influenza and Respiratory Viruses With COVID-19 Public Health Measures.// Mayo Clinic Proceedings, 96(12), 3042–3052. https://doi.org/10.1016/j.mayocp.2021.09.004)) * Doroshenko reported receiving personal fees from [[:pharmaceutical_companies:Sanofi]] for an advisory role * He also reported that his employer, the [[:University of Alberta]], was paid additional funds in research grants from the [[:Canadian Institutes of Health Research]] (CIHR), [[Public Health Agency of Canada]], [[Alberta Health Services]], and the [[:University Hospital Foundation]] (also listed as "University of Alberta Hospital Foundation"). * The study found that the public health measures Doroshenko helped put in place were "associated with a substantial reduction in influenza and NIRV infections in Alberta." * //The Combined Effect of Vaccination and Nonpharmaceutical Public Health Interventions-Ending the COVID-19 Pandemic//((Doroshenko, A. (2021). //The Combined Effect of Vaccination and Nonpharmaceutical Public Health Interventions—Ending the COVID-19 Pandemic.// JAMA Network Open, 4(6), e2111675. https://doi.org/10.1001/jamanetworkopen.2021.11675)) * Doroshenko reported receiving personal fees from [[:pharmaceutical_companies:Sanofi]] for an advisory role * He also reported that his employer, the [[:University of Alberta]], was paid additional funds in research grants from the [[:Canadian Institutes of Health Research]] (CIHR), [[Public Health Agency of Canada]], [[Alberta Health Services]], and the [[:University Hospital Foundation]] (also listed as "University of Alberta Hospital Foundation"). ===== External links ===== * [[https://wiki.whiteroseintelligence.com/en/Alexander-Doroshenko|White Rose Wiki]]